The Profile
The Chemist Who Makes Molecules Do Things
In Somers Point, New Jersey - a shore town, population modest, ambitions unclear - a kid developed an unusual obsession with how molecules bind to each other. That kid is now the reason three drugs are on pharmacy shelves that wouldn't exist otherwise, and why the phrase "that target is undruggable" has largely retired from serious scientific vocabulary.
Gregory L. Verdine earned his PhD at Columbia in 1986, studying under Koji Nakanishi and Maria Tomasz, with a thesis that tracked how mitomycin C attaches itself to DNA strands - a very specific question that turned out to be a preview of his entire career: how do you get a molecule to do something precise inside a living system? He did his postdoc at MIT and Harvard Medical School on an NIH fellowship, then joined the Harvard faculty in 1988 and never really left - except when he stepped down from tenure in 2013 to run a company, which tells you everything you need to know about how seriously he takes the translation from bench to bedside.
"The people here have such high energy, are extremely excited about what they're doing, are very committed, are very collegial with each other, and have few silos or barriers."- Greg Verdine on building biotech teams
The stapled peptide story is where things get genuinely strange. Peptides - short chains of amino acids - are theoretically capable of binding to a huge range of biological targets, including the so-called "undruggable" ones that small molecules can't reach and antibodies can't penetrate. The problem: they fold up and fall apart before they can do anything useful. Verdine and his collaborator Christian Schafmeister figured out how to put a physical crosslink - a "staple" - into the peptide chain that holds it in the right shape and protects it long enough to get inside a cell. A new class of drugs, invented. He named what they were for - "drugging the undruggable" - and the phrase stuck so thoroughly that it now appears in papers by people who have no idea who coined it.
Three Approaches to the "Undruggable" Problem
Verdine's innovations address what conventional drug design couldn't reach:
Stapled Peptides
Hydrocarbon crosslinks lock peptides into their active conformation. Result: molecules that penetrate cells and engage targets inside - combining antibody-like binding with small-molecule access.
Molecular Glues
At Warp Drive Bio, Verdine's team built the first discovery engine designed to create "molecular glues" - compounds that force two proteins together rather than blocking one, opening an entirely new pharmacology.
Fungal Small Molecules
LifeMine Therapeutics mines the fungal biosphere - where genetically-encoded small molecules remain largely unexplored - for compounds with new mechanisms of action that chemistry alone can't predict.
The company list is where most profiles would simply become a table, but the timeline matters here. Gloucester Pharmaceuticals gave the world romidepsin - an FDA-approved cancer drug, built from a natural product, eventually acquired by Celgene for around $640 million. Enanta Pharmaceuticals led to paritaprevir, an anti-hepatitis C drug approved by the FDA in 2014 through an AbbVie partnership. These are real drugs on real shelves treating real patients. Warp Drive Bio, which Verdine co-founded with George Church and James Wells, was later acquired by Revolution Medicines. FogPharma, launched in 2016 with Sir David Lane, became Parabilis Medicines in 2024 and continues working on cell-penetrating miniproteins. The list goes to 13 companies and keeps going.
What makes the career unusual isn't the volume - it's the mode. Verdine ran two companies simultaneously for six years while maintaining ties to Harvard. He stepped down from one of academia's most coveted positions to become a CEO. He has worked as a venture partner at Apple Tree Partners, Third Rock Ventures, and WuXi Healthcare Ventures before landing at Andreessen Horowitz in July 2023. Most scientists pick a lane. Verdine drives in all of them at once.
At a16z, he brings something that pure capital can't provide: direct knowledge of what it feels like to have a molecule that works on a bench and has to survive trials, regulatory hurdles, manufacturing, and a market that doesn't know it needs what you've made. He's not advising from a distance. He's been the person in the room where those decisions happen. For founders working on the hard problems in biology - the ones where the targets have historically been written off - that's not a resume credential. That's a direct line to someone who already solved a version of their problem.
He is currently CEO of LifeMine Therapeutics, the company he co-founded with WeiQing Zhou in 2016 to search the fungal world for new medicines. The fungal biosphere contains some of the most complex and diverse small molecules on earth - many of which have never been characterized, let alone tested therapeutically. Verdine's bet is that the next generation of drugs isn't waiting in a chemist's computer model. It's growing in a petri dish.